Evidence mapPaperPMID 1939657Full record

ArticleThe Journal of clinical investigation1991

Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia.

D A Hardman, C R Pullinger, R L Hamilton, J P Kane, M J Malloy

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 54 citations in OpenAlex.

  1. Novel protein-truncating variant in theAtherosclerosis plus · 2022
    Article
  2. Review
  3. Article
  4. Optic atrophies in metabolic disorders.Molecular genetics and metabolism
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

D A HardmanCardiovascular Research Institute, University of California, San Francisco 94143-0130.
C R Pullinger
R L Hamilton
J P Kane
M J Malloy
University of California, San Francisco · US

Funding

ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMAM01RR000079 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1985 to 2005
$24.0M
SYNTHESIS AND SECRETION OF NORMAL AND ABNORMAL LIPOPROTEINSP50HL014237 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1985 to 1996
TRAINING PROGRAM IN HEART AND VASCULAR DISEASEST32HL007192 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1985 to 1991
NCRR NIH HHS 5-M01-RR00079NHLBI NIH HHS HL 07192NHLBI NIH HHS HL 14237
6 · The paper itself

Abstract

We have previously described a disorder, normotriglyceridemic abetalipoproteinemia, that is characterized by the virtual absence of plasma low density lipoproteins and complete absence of apoB-100, but with apparently normal secretion of triglyceride-rich lipoproteins containing apoB-48. The patient's plasma lipoproteins were shown on polyacrylamide gels and by antibody mapping to have a new truncated apoB variant, apoB-50, circulating along with her apoB-48. We have found this individual to be homozygous for a single C-to-T nucleotide substitution at apoB codon 2252, which produces a premature in-frame stop codon. Thus, this is a rare example of homozygous hypobetalipoproteinemia. Electron photomicrographs revealed that the diameters of particles in the d less than 1.006 g/ml lipoprotein fraction, in both the postprandial and postabsorptive state, are bimodally distributed. The molar ratio of apoE to apoB in these particles is 3.5:1, similar to normal VLDL. The plasma LDL interval contains both spherical and cuboidal particles. Autologous reinfusion of labeled d less than 1.006 g/ml lipoproteins showed exponential disappearance from plasma, with an apparent half-removal time of 50 min, somewhat slower than for normal chylomicrons but within the normal range for VLDL. The calculated production rate for apoB was within the normal range in this subject. A very small amount of label was found briefly in the IDL fraction, but none at any time in LDL or HDL. Therefore, because LDL particles that contain apoB-50 lack the putative ligand domain of the LDL receptor, we conclude that the very low level of LDL is due to the rapid removal of the abnormal VLDL particles before their conversion to LDL can take place.

Indexed as

AbetalipoproteinemiaApolipoproteins BApolipoproteins EBase SequenceHumansImmunoblottingLipoproteinsLipoproteins, LDLLipoproteins, VLDLMolecular Sequence DataPeptide MappingApolipoproteins BApolipoproteins ELipoproteinsLipoproteins, LDLLipoproteins, VLDL

Identifiers

PMID1939657
PMCPMC295713
OpenAlexW2023069842

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.